Loading clinical trials...

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

NCT06295562•China Medical University Hospital

Summary

This study will conduct 3 intervention trials with 44 different participants in each trial, with 22 participants will undergo in-laboratory overnight polysomnograms (PSGs) at one night of medication intervention, and the other 22 at taking placebo (contained starch) 1 h before sleep. Three medication regimens will be tested: (1) atomoxetine 80mg combined with oxybutynin 5mg; (2) venlafaxine 37.5mg; and (3) atomoxetine 80mg combined with trazodone 100mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•apnea-hypopnea index ≥ 15 hr-¹

Exclusion Criteria

•the presence of pulmonary, cardiac, neurologic, or other active severe medical or psychiatric diseases
•current use of continuous positive airway pressure therapy
•use of drugs that might interact with the investigational medication or known to affect sleep during the trial or 1 month before the study
•known allergy to the investigational medication
•current smoking
•heavy alcohol drinking (male \> 14 drinks and women \>7 drinks per week)
•pregnant or lactating
•periodic limb movement index ≤ 15hr-1
•the presence of sleep-related hypoventilation

Locations (1)

China Medical University Hospital

Taichung, Taiwan

Key Dates

Start Date

November 5, 2024

Primary Completion Date

October 10, 2025

Completion Date

October 22, 2025

Last Updated

December 2, 2025

Enrollment

ACTUAL participants

Conditions

Obstructive Sleep Apnea of Adult

Interventions

Atomoxetine 80mg combined with oxybutynin 5mg

DRUG

Venlafaxine 37.5mg

DRUG

Atomoxetine 80mg combined with trazodone 100mg

DRUG

Placebo

DRUG

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

NCT06430957

Obstructive Sleep Apnea Risk ManagementPostoperative Complications+2 more

View study

RECRUITING

A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

NCT03307330

Obstructive Sleep Apnea of Adult

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

Inclusion Criteria

Exclusion Criteria

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome.

Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device

Mandibular Advancement Device (MAD) in Pregnant Women With Obstructive Sleep Apnea (OSA)

the Pathophysiology of the Onset of Atrial Fibrillation in Obstructive Sleep Apnea